Appili Therapeutics提供了其PRESECO第三阶段试验的注册更新，
该试验评估口服抗病毒药物Favipiravir作为COVID-19的早期治疗方法
生物制药公司Appili Therapeutics Inc.（以下简称“ Appili”）专注于开发用于传染病的药物，
今天宣布，其3期PRESECO（推广SEvere COvid-19）临床试验正在美国20个地点中的12个积极招募参与者。
根据目前的预测，
Appili认为
它将在2021年3月下旬达到提供临时数据读数所需的入学门槛。
PRESECO：
is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.
In addition, the Company is pursuing regulatory approvals to expand PRESECO into sites in Mexico, Brazil, and Colombia.
Along with generic producer Dr. Reddy’s, the company’s favipiravir-based product for treating early onset COVID-19
was quietly submitted as well to Health Canada for Market Authorization, as reported by TrialSite on Dec. 22.